Gosogliptin

Gosogliptin (INN; trade name SatRx) is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors (also called gliptins). It was discovered and developed through Phase 2 by Pfizer. It is approved for use in Russia. Gosogliptin (INN; trade name SatRx) is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors (also called gliptins). It was discovered and developed through Phase 2 by Pfizer. It is approved for use in Russia.